// App-Quantinova.ai

THU0328 : SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN SYSTEMIC SCLEROSIS: RESULTS FROM THE OPEN-LABEL PERIOD OF THE PHASE 3 FOCUSSCED TRIAL

Researchers

Presenter

  • D. Khanna

Principal Investigators

  • C. J. F. Lin

  • H. Spotswood

  • J. Siegel

  • D. Furst

  • C. Denton

Medical Centers

  • University of Michigan - Ann Arbor - United States of America

  • Genentech, Inc., South San Francisco, California, United States of America

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • University of California Los Angeles - Los Angeles - United States of America

  • Kings College London, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Scleroderma

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • N/A

Drug/Treatment

  • Tocilizumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved